Scarica l'app Stockscreener
15.75
7.13%
-1.21
Dopo l'orario di chiusura:
15.51
-0.24
-1.52%
Precedente Chiudi:
$16.96
Aprire:
$16.31
Volume 24 ore:
187.81K
Relative Volume:
0.15
Capitalizzazione di mercato:
$62.82M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-20.45
EPS:
-0.77
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
-2.84%
1M Prestazione:
+241.65%
6M Prestazione:
+2,066%
1 anno Prestazione:
+2,988%
Intervallo 1D:
$15.51
$16.64
Intervallo di 1 settimana:
$12.55
$18.20
Portata 52W:
$0.2739
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - ForexTV.com
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - GlobeNewswire Inc.
Monopar Therapeutics announces public stock offering - Investing.com
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short Interest - MarketBeat
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners are retail investors who got richer after stock soared 208% last week - Simply Wall St
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance
Monopar Therapeutics Skyrockets 400% on Licensing Deal - MSN
Wilmette startup's stock soars as it buys back the drug its founder made from Big Pharma - Crain's Chicago Business
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap DownHere's What Happened - MarketBeat
What's Going On With Monopar Therapeutics Shares Friday? - Benzinga
Monopar Therapeutics Secures License for Wilson Disease Treatment - Yahoo Finance
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Monopar Therapeutics Skyrockets 400% On Licensing Deal - Barchart
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Monopar Therapeutics Inc. has entered into an agreement to acquire worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. - Marketscreener.com
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - MarketWatch
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33% - MSN
Viking Therapeutics stock soars on heels of Q3 beat - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Monopar secures global license for Wilson disease drug - Investing.com
Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon - Barchart
Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday?AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga
Monopar Up 450%Were You On Board? - RTTNews
Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com
Monopar (MNPR) Experiences Stock Boost After An Agreement - Stocks Telegraph
Monopar Shares Surge on AstraZeneca Licensing Deal -- Update - MarketWatch
Monopar stock soars to 52-week high, hits $8.75 - Investing.com
Monopar secures global license for Wilson disease drug By Investing.com - Investing.com South Africa
Monopar Shares Rise on AstraZeneca Licensing Deal - Marketscreener.com
Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate - Marketscreener.com
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Monopar Therapeutics Unveils Promising Radiopharmaceutical Data - TipRanks
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 - The Manila Times
(MNPR) Trading Advice - Stock Traders Daily
Monopar Therapeutics Expands Portfolio with New Patent Filing - Yahoo Finance
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decrease in Short Interest - MarketBeat
Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial - Yahoo Finance
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers - The Manila Times
Monopar Presents Data Showcasing the Appeal of uPAR as a - GlobeNewswire
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):